Whales with a lot of money to spend have taken a noticeably bearish stance on MorphoSys.
Looking at options history for MorphoSys MOR we detected 27 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 59% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $91,390 and 25, calls, for a total amount of $2,736,244.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $15.0 for MorphoSys over the recent three months.
Volume & Open Interest Development
In today's trading context, the average open interest for options of MorphoSys stands at 2475.62, with a total volume reaching 36,484.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in MorphoSys, situated within the strike price corridor from $10.0 to $15.0, throughout the last 30 days.
MorphoSys 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MOR | CALL | SWEEP | BULLISH | 02/16/24 | $10.00 | $650.0K | 3.7K | 1.1K |
| MOR | CALL | SWEEP | BULLISH | 03/15/24 | $12.50 | $250.0K | 4.1K | 644 |
| MOR | CALL | SWEEP | BEARISH | 02/16/24 | $12.50 | $240.0K | 4.9K | 1.1K |
| MOR | CALL | TRADE | BEARISH | 02/16/24 | $12.50 | $200.1K | 4.9K | 682 |
| MOR | CALL | TRADE | BEARISH | 02/16/24 | $12.50 | $147.0K | 4.9K | 1.7K |
About MorphoSys
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Following our analysis of the options activities associated with MorphoSys, we pivot to a closer look at the company's own performance.
MorphoSys's Current Market Status
- With a trading volume of 31,981,433, the price of MOR is up by 1.39%, reaching $17.51.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 36 days from now.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MorphoSys options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
